Carbon Dioxide Insufflation Colonoscopy in IBD Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02563132 |
Recruitment Status :
Completed
First Posted : September 29, 2015
Last Update Posted : June 1, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Colonoscopy Carbon Dioxide Inflammatory Bowel Disease | Procedure: Carbon dioxide insufflation | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 64 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Diagnostic |
Official Title: | Carbon Dioxide Insufflation Colonoscopy in Inflammatory Bowel Disease Patients |
Study Start Date : | October 2015 |
Actual Primary Completion Date : | May 2016 |
Actual Study Completion Date : | May 2016 |

Arm | Intervention/treatment |
---|---|
Experimental: Carbon dioxide insufflation colonoscopy (CO2)
Carbon dioxide during both insertion and withdrawal phase of the colonoscopy.
|
Procedure: Carbon dioxide insufflation
Carbon dioxide insufflation during diagnostic colonoscopy |
No Intervention: Air insufflation colonoscopy (AI)
Air insufflation during both insertion and withdrawal phase of the colonoscopy.
|
- Bloating score 1 hour after the colonoscopy [ Time Frame: 1 hour ]Bloating severity on continuous scale 0-10 (0 = none, 10 = worst) 1 hour after colonoscopy

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- known diagnosis of Crohn´s disease and ulcerative colitis
- indication for diagnostic colonoscopy
- informed consent
- unsedated or minimally sedated procedure (< 3 mg of midazolam)
Exclusion Criteria:
- planned incomplete or therapeutic procedure
- deep sedation or general anesthesia
- intestinal resection longer than ileocecal resection
- isolated gastroduodenal or jejunal location of Crohn´s disease (L4)
- ulcerative proctitis (E1)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02563132
Czech Republic | |
Digestive Diseases Center - Vitkovice Hospital | |
Ostrava, Czech Republic, 703 84 |
Responsible Party: | Premysl Falt, M.D., Ph.D., Vitkovice Hospital |
ClinicalTrials.gov Identifier: | NCT02563132 History of Changes |
Other Study ID Numbers: |
DDC VN 08 |
First Posted: | September 29, 2015 Key Record Dates |
Last Update Posted: | June 1, 2016 |
Last Verified: | May 2016 |
colonoscopy carbon dioxide inflammatory bowel disease |
Intestinal Diseases Inflammatory Bowel Diseases Gastrointestinal Diseases Digestive System Diseases Gastroenteritis |